347 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
University of Applied Sciences Darmstadt
12
Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.
Broad Institute of Mit and Harvard
40
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
West China Hospital of Sichuan University
4
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
University of Milan
10
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
Biofocus
8
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Sungkyunkwan University
24
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Sichuan University
14
Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
Shanghai Institute of Materia Medica
18
Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
Shenyang Pharmaceutical University
45
Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.
Shenyang Pharmaceutical University
2
Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Orchid Chemicals & Pharmaceuticals
1
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.
University of Minnesota
9
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Guangzhou Institute of Biomedicine and Health
11
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.
Shandong University
5
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
University of Minnesota
21
Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
University College London
11
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
St. Jude Children'S Research Hospital
5
Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Novartis Institutes For Biomedical Research
4
Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
University of Florida
2
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Shandong University
3
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Istituto Ortopedico Rizzoli (Ior)
8
Bicyclic tetrapeptides as potent HDAC inhibitors: effect of aliphatic loop position and hydrophobicity on inhibitory activity.
University of Rajshahi
8
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
University of Rajshahi
12
1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
Sapienza University of Rome
16
Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Nippon Pharmaceutical Chemicals
18
Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Shandong University
21
Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
TBA
16
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Roche Pharmaceutical Research and Early Development
6
Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
University of Bologna
38
Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Chinese Academy of Sciences
8
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.
Merck Research Laboratories
36
Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
University of Siena
16
4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
University of Ferrara
11
Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
University of Milan
8
Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
Shandong University
3
Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
Sapienza University of Rome
15
Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Broad Institute of Mit and Harvard
5
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Heinrich Heine Universit£T
6
Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
Kyoto Prefectural University of Medicine
6
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Roche R & D Center China
15
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
University of Illinois At Chicago
6
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
Graduate School of Life Science and Systems Engineering
76
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Kyoto Prefectural University of Medicine
23
Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
Guru Ghasidas University
18
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ¿F508-CFTR.
TBA
6
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Broad Institute of Harvard and Mit
37
Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Irbm/Merck Research Laboratories
4
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
Istituto Di Ricerche Di Biologia Molecolare
6
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.
Waseda University
2
Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
Sapienza University of Rome
63
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Merck Research Laboratories
33
A series of novel, potent, and selective histone deacetylase inhibitors.
Irbm/Merck Research Laboratories
4
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
Crest Research Project
14
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
Sapienza University of Rome
1
Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Dac
12
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
University of Illinois At Chicago
4
Synthesis of a new trifluoromethylketone analogue of l-arginine and contrasting inhibitory activity against human arginase I and histone deacetylase 8.
Drexel University
6
Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.
University of Wisconsin-Milwaukee
51
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
S*Bio
5
Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Taipei Medical University
27
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
Broad Institute of Harvard and Mit
20
Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Universita` Degli Studi Di Siena
2
Structure and property based design, synthesis and biological evaluation of¿-lactam based HDAC inhibitors.
Yonsei University
13
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
TBA
4
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
The Scripps Research Institute
6
Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
Universidade De Vigo
37
Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
S*Bio
4
Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.
University of Salerno
18
Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
Novartis Institutes For Biomedical Research
6
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.
Graduate School of Life Science and Systems Engineering
26
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Curis
2
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Ortho-Biotech Oncology Research & Development
2
Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
China Pharmaceutical University
16
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
Methylgene
5
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Sigma-Tau Research and Development
24
Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Irbm/Merck Research Laboratories
6
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
R&D Sigma-Tau
22
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Merck Research Laboratories
37
N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
S*Bio
39
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Merck Research Laboratories
31
2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
Irbm-Merck Research Laboratories Rome
19
Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
China Pharmaceutical University
5
Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
Institute of Organic Synthesis
22
Novel Carbamate-Based o-aminobenzamide Derivatives as Potent Antigastric Carcinoma Agents via Disrupting NAD+ Salvage Synthesis.
University of South China
29
The role of silicon in drug discovery: a review.
Pharmaceutical Technologies, Future Production: Chemicals, Council for Scientific and Industrial Research (CSIR)
5
Bifunctionality and Antitumor Efficacy of ZG-126, a Vitamin D Receptor Agonist/Histone Deacetylase Inhibitor Hybrid Molecule.
McGill University
19
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.
University of Bonn
37
Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases.
Ocean University of China
17
HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation.
Shandong University
54
Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy.
Southwest Jiaotong University
24
Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity.
Zhejiang University
9
Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia.
Shandong University
17
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents.
Central University of Punjab
16
Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells.
University of Bonn
48
An Amazing 30-Year Journey around the DABO Family: A Medicinal Chemistry Lesson on a Versatile Class of Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.
Sapienza University of Rome
13
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy.
Gannan Medical University
3
Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy.
Gannan Medical University
20
Discovery of WDR5-MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia.
China Pharmaceutical University
19
Multicomponent syntheses enable the discovery of novel quisinostat-derived chemotypes as histone deacetylase inhibitors.
University of Bonn
33
Indolo[3,2-c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy.
China Pharmaceutical University
6
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.
University of Bonn institution
31
Discovery of N-Phenyl-5-propyl-1H-pyrazole-3-carboxamide, with Selective Inhibition and Degradation of HDAC6 for the Treatment of Acute Liver Injury.
Anhui Medical University
2
Discovery of cloxiquine derivatives as potent HDAC inhibitors for the treatment of melanoma via activating PPARγ.
Xinxiang Medical University
16
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.
Heinrich Heine University Dusseldorf
9
Synthesis and Evaluation of 9-epi-Koshidacin B as Selective Inhibitor of Histone Deacetylase 1.
University of Kalyani
21
Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds.
Adam Mickiewicz University
21
Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.
Ocean University of China
14
Synthesis and application of small molecules approved for the treatment of lymphoma.
The First Affiliated Hospital of Zhengzhou University
33
Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma.
Sichuan University
14
Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
Ocean University of China
17
Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity.
Northwest A&F University
30
Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy.
Southern Medical University
32
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
University of Modena and Reggio Emilia
44
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Jadavpur University
14
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.
Guizhou Medical University
68
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Shandong University
36
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.
Shandong University
21
Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.
Ocean University of China
35
Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.
University of Chinese Academy of Sciences
21
Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death.
Shandong University
23
Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo.
Shenyang Pharmaceutical University
20
Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease.
Northwest A&F University
19
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Merck Research Laboratories
5
Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment.
Manipal Academy of Higher Education
4
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit.
Southeast University
40
Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Chinese Academy of Medical Sciences & Peking Union Medical College
13
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib.
Heinrich Heine University Dusseldorf
3
Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC.
Guizhou Medical University
9
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Guru Ghasidas University
7
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
Graduate School of Life Science and Systems Engineering
32
Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity.
Sungkyunkwan University
14
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
Graduate School of Life Science and Systems Engineering
13
Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
Keimyung University
32
Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.
National Taiwan University
34
Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.
China Pharmaceutical University
26
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.
Ocean University of China
56
Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.
Taipei Medical University
11
Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
China Pharmaceutical University
6
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
The University of Tokyo
63
Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response.
Xuzhou Medical University
9
Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy.
University of Toronto Mississauga
16
Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice.
Sichuan University
4
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
AstraZeneca
14
Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
Shandong University
25
-(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity.
National and Kapodistrian University of Athens
5
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase
University of Bonn
3
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer.
Birla Institute of Technology and Science-Pilani Hyderabad
2
Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
Universidade De Vigo
58
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
Ghent University
25
Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
Sapienza University of Rome
25
Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-β-Induced Idiopathic Pulmonary Fibrosis.
National Taiwan University
7
Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
Shandong University
36
Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.
Nankai University
118
Electrophilic MiniFrags Revealed Unprecedented Binding Sites for Covalent HDAC8 Inhibitors.
Hun-Ren Research Centre for Natural Sciences
14
Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.
Zhengzhou University
46
Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Wuyi University
11
Design, synthesis, and anti-inflammatory activity characterization of novel brain-permeable HDAC6 inhibitors.
Chinese Academy of Sciences
2
Design, synthesis, and biological evaluation of novel HDAC inhibitors with a 3-(benzazol-2-yl)quinoxaline framework.
Southeast University
11
Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones.
University of Toledo
21
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
IRBM Science Park
32
Bioactive Aurones, Indanones, and Other Hemiindigoid Scaffolds: Medicinal Chemistry and Photopharmacology Perspectives.
Universite Grenoble Alpes
173
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.
Univ. Grenoble Alpes
3
The importance of indole and azaindole scaffold in the development of antitumor agents.
Qingdao University of Science and Technology
18
Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Northwest A&F University
38
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Scripps Research
29
Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Sungkyunkwan University
4
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
Nagoya City University
72
The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.
Aligarh Muslim University
68
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Menoufia University
35
Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
Nanchang University
4
Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
Peking Union Medical College
19
Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.
Stony Brook University
26
Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties.
Martin-Luther University of Halle-Wittenberg
11
Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
China Pharmaceutical University
9
Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
Shanghai Institute of Pharmaceutical Industry
2
Design and synthesis of phthalimide-type histone deacetylase inhibitors.
The University of Tokyo Yayoi
17
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
University of Toronto Mississauga
10
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Charles River Laboratories
3
Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
Ocean University of China
8
Discovery of Benzylpiperazine Derivatives as CNS-Penetrant and Selective Histone Deacetylase 6 Inhibitors.
Kansai University
20
Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
Bharati Vidyapeeth's College of Pharmacy
38
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.
Ocean University of China
15
Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
Sun Yat-Sen University
3
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
Taipei Medical University
1
Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Peking Union Medical College
16
Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
Qingdao University Medical College
5
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.
Birla Institute of Technology and Science-Pilani Hyderabad Campus
34
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
National Institute of Pharmaceutical Education and Research (NIPER)
31
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
China Pharmaceutical University
24
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
University of Bonn
13
First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
University of Toledo
3
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Taipei Medical University
24
From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Chengdu University of Traditional Chinese Medicine
5
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Nirma University
6
HIV latency reversal agents: A potential path for functional cure?
S£O Paulo State University (Unesp)
17
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhengzhou University
4
Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Guizhou Medical University
25
Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
China Pharmaceutical University
21
Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Southeast University
25
Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.
Ocean University of China
21
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
University of Toronto Mississauga
29
Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their
Bharati Vidyapeeth's College of Pharmacy
12
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
Julius Maximilian University of W£Rzburg
7
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
China Pharmaceutical University
43
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A
Shanghaitech University
4
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
China Pharmaceutical University
8
Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity.
West China Hospital of Sichuan University
5
Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
Guizhou Medical University
16
Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Shandong University
42
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Shandong University
6
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Children'S Hospital Affiliated To Zhengzhou University
20
Role of Fluorination in the Histone Deacetylase 6 (HDAC6) Selectivity of Benzohydroxamate-Based Inhibitors.
Italfarmaco
31
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
University of Illinois At Chicago
21
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Heinrich-Heine-Universit£T D£Sseldorf
20
Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
Taipei Medical University
7
Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
University of Sharjah
2
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Nankai University
37
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Shenzhen Technology University
28
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
University of East Anglia
10
Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Taipei Medical University
23
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
The University of Queensland
46
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Shanghai Institute of Materia Medica
32
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.
Merck
10
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
The George Washington University
18
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Leipzig University
26
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
University of Toronto Mississauga
42
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
A*Star
20
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Charles River Discovery
15
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Taipei Medical University
20
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Shandong University
3
Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.
Sichuan University
19
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
Merck
13
Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
Sichuan University
28
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
University of Toronto Mississauga
6
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
Sapienza University of Rome
10
New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
Universidad San Pablo-Ceu
12
Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Heinrich-Heine-Universit£T D£Sseldorf
43
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
University of Connecticut
22
Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy.
Wuyi University
107
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
Indian Csir-Central Drug Research Institute
5
Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
TBA
45
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
University of Applied Sciences
39
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
National Center For Advancing Translational Sciences
17
Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
Jadavpur University
22
Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Heinrich-Heine-University D£Sseldorf
8
Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
Umr Cnrs 7285
17
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
University of Toronto Mississauga
17
N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
Taipei Medical University
3
Recent advances in class IIa histone deacetylases research.
Heinrich-Heine-Universit£T D£Sseldorf
2
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Sichuan University and Collaborative Innovation Center of Biotherapy
17
Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors.
Chinese Academy of Sciences
28
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
University of Illinois At Chicago
26
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
Ocean University of China
16
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Shandong University
42
Discovery of Thieno[2,3-
Sichuan University and Collaborative Innovation Center of Biotherapy
4
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
Qingdao University
20
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Heinrich-Heine-Universit£T D£Sseldorf
19
Identification of novel quinazoline derivatives as potent antiplasmodial agents.
University of Lille
2
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Institute of Biotechnology of The Czech Academy of Sciences
38
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
TBA
20
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Charles River Discovery (Previously Biofocus)
17
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Shandong University
7
Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from
University of Wisconsin-Milwaukee
3
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
University of Connecticut
40
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
China Pharmaceutical University
3
Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.
Therachem Research Medilab (India)
15
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
University of Connecticut
36
Biological function and small molecule inhibitors of histone deacetylase 11.
Ocean University of China
19
Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
University of Regensburg
4
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
University of Milan
38
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Nestle Skin Health
36
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
University of Navarra
11
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms.
Mazandaran University of Medical Sciences
4
Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Minia University
11
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
Second Military Medical University
6
Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming.
University of Bologna
5
Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Taipei Medical University
22
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.
Forma Therapeutics
2
Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
Csir-Indian Institute of Integrative Medicine
24
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
University of Regensburg
10
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Taipei Medical University
10
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
University of Reims Champagne
17
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
Ghent University
19
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Novartis Institutes For Biomedical Research
27
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Taipei Medical University
12
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Medical University of South Carolina
15
Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Shandong University
6
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Taipei Medical University (Tmu)
35
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Second Military Medical University
6
Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Heinrich-Heine-Universit£T D£Sseldorf
17
Antimitotic amides for the treatment of cancer and proliferative disorders
Frost Biologic
59
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
Nurix Therapeutics
152
Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
Blueray Therapeutics (Shanghai)
5
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.
Fred Hutchinson Cancer Research Center
129
Pyrimidine compounds as mTOR and PI3K inhibitors
Development Center For Biotechnology
404
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
6
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Novartis Pharma
2
Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-Based Inhibitors.
University of California Irvine
24
1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF
Chong Kun Dang Pharmaceutical
15
Harnessing Enzymatic Promiscuity in Myxochelin Biosynthesis for the Production of 5-Lipoxygenase Inhibitors.
Hans Knöll Institute
20
Synthesis, Molecular Modeling, and Biological Evaluation of Novel 1, 3-Diphenyl-2-propen-1-one Based Pyrazolines as Anti-inflammatory Agents.
Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz
45
Solution phase parallel synthesis of substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: selective serotonin 5-HT(6) receptor antagonists.
Chemical Diversity Research Institute
7
Synthesis,MolecularModeling, and Biological Evaluation of Novel Tetrahydro-ß-Carboline Hydantoin and Tetrahydro-ß-Carboline Thiohydantoin Derivatives as Phosphodiesterase 5 Inhibitors
German University In Cairo
4
Novel Anti-inflammatory Activity of Epoxyazadiradione against Macrophage Migration Inhibitory Factor: INHIBITION OF TAUTOMERASE AND PROINFLAMMATORY ACTIVITIES OF MACROPHAGE MIGRATION INHIBITORY FACTOR.
Council of Scientific and Industrial Research (Csir) Indian Institute of Chemical Biology
3
COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
Korea Research Institute of Chemical Technology
7
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
F. Hoffmann-La Roche
4
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.
Yamanouchi Pharmaceutical
15
Discovery of a novel member of the histamine receptor family.
The Centre For Addiction and Mental Health
5
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
Torrey Pines Institute For Molecular Studies
16
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).
Roche Bioscience
3
Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor.
Medical University of South Carolina